DIMI

DimiCare Biotech is a biotechnology startup and spin-off from the University Côte d'Azur (UniCA) focused on developing a new generation of precision antibiotics to combat multidrug-resistant pathogens. The company utilizes its proprietary Antimicrobial Research and Optimization Workflow (ARROW) platform to identify and characterize highly specific compounds with a reduced propensity for resistance. Its lead development program, DCB001, is a topical drug candidate targeting Staphylococcus aureus-associated skin infections, including MRSA. DimiCare aims to address the global health crisis of antibiotic resistance by delivering effective, targeted therapies with minimal environmental impact. The company integrates medicinal chemistry expertise with AI-boosted research tools to accelerate drug discovery and development.